Watchlist

Watchlist
Arena Pharmaceuticals, Inc. (ARNA)
Arena Pharmaceuticals, Inc. (ARNA)
Arena Pharma Races Toward Q1 2018 Trial Results
Management Changes What many are not aware of about Arena Pharmaceuticals (ARNA) is that the company is emerging from a bungling past management that not only did not know how to communicate properly with Wall Street but also needlessly mishandled and delayed the real value in its surprisi…
Week In Review: China Life Science Deals Total $550 Million
Deals and Financings Pfizer (NYSE: [[PFE]]) signed a $226 million agreement for China/Asian rights to Cresemba (isavuconazole), an antifungal drug developed by Swiss pharma Basilea (BPMUF). Previously, Pfizer acquired rights for Cresemba in Europe, Russia, Turkey and Israel. In the latest …
Arena Pharmaceuticals Inks China Deal On 2 Pipeline Candidates
Arena Pharmaceuticals ( ARNA ) has announced that the company has partnered with Everest Medicines on Raliepag and Etrasimod in China and other Pacific region countries. The deal pays Arena $12 million in upfront cash and includes up to $212 million in milestones. In addition, Arena will rec…
Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China
SAN DIEGO , Dec. 5, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, and Everest Medicines Limited ("Everest"), a C-Bridge Capital-backed biopharmaceut…
Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China
Arena eligible to receive up to $224M , including upfront and milestone payments, in addition to royalties SAN DIEGO , Dec. 5, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across …
Biotech: Biding Its Time
Biotech Pulse The months of October and November have been unfavorable for biotechs as the sector has witnessed a sharp pullback. The Nasdaq Biotechnology Index ( IBB ), shown below, retreated 12% from its 52-week high posted in early October. Nasdaq Biotechnology Index ETF ((IBB)) Dur…
Arena Q3: Loss But Progress On Pipeline
Last week Arena Pharmaceuticals ( ARNA ) reported its Q3 2017 earnings, and investors can clearly see why the company is a speculative play. Revenue from the Belviq franchise and the toll manufacturing are underwhelming when stacked up against operating costs, research and development costs,…
Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview
The bioscience sector is poised with substantial growth and galvanized by promising prospects. One can earn 90% profits in one day, following a positive catalyst event. Stellar companies such as Kite Pharma (NASDAQ: KITE ), Amicus Therapeutics (NASDAQ: FOLD ), Conatus Pharmaceuticals (NASDAQ: …
Arena completes enrollment in mid-stage etrasimod study in UC; shares up 1%
Arena Pharmaceuticals ( ARNA +1.4% ) hits the enrollment target of 157 subjects in a Phase 2 clinical trial evaluating etrasimod in patients with ulcerative colitis (UC). More news on: Arena Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more …
Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis
SAN DIEGO , Nov. 10, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announcedthat it has completed full enrollment in the etrasimod Phase 2 study in ulcerative colitis (UC). Etrasimod is an investigational-stage, oral, next-generation, sphingosin…
Arena Pharmaceuticals' (ARNA) CEO Amit Munshi on Q3 2017 Results - Earnings Call Transcript
Arena Pharmaceuticals, Inc. (ARNA) Q3 2017 Earnings Conference Call November 07, 2017 04:30 PM ET Executive Kevin Lind - CFO Amit Munshi - President and CEO Analyst Joseph Schwartz - Leerink Partners Jason Butler - JMP Securities Jessica Fye - JP Morgan Alan Carr - Need…
Arena Pharmaceuticals, Inc. (ARNA)